Liquid Biopsy Revolutionizing Cancer Care, But Costs Continue To Inhibit Global Potential
For much of the world, the full promise of liquid biopsy exceeds purchasing power.
Liquid biopsy represents potential advantages over traditional approaches to cancer surveillance, treatment selection and recurrence monitoring. But one size does not fit all, requiring tailored solutions for less developed markets.
You may also be interested in...
This year’s annual HLTH meeting drew more than 9,000 people to Las Vegas from 13-16 November and hundreds of exhibitors. In this first part of a two-part roundup, Medtech Insight highlights interviews with C-suite executives at Mirvie, Grail, Biofourmis, Komodo Health and Babson Diagnostics.
The FDA has approved Angle’s Parsortix circulating tumor cell cancer capturing system, which the company believes will be a paradigm shift for liquid biopsy in the US and heighten competition in the oncology diagnostics space.
In this first edition of Report Digest, UK-based reporter Barnaby Pickering discusses the liquid biopsy for oncology market with analyst Phil Greenfield. The two discuss the main market drivers and what experts think will occur in the sector in future years.